Similarly, high TOP2A levels may suggest an increased sensitivity to topoisomerase II inhibitors42,43 in RAS wild-type CRC and prompt the exploration of agents not routinely considered as standard-of-care. The gene discussed is TOP2A; the disease is colorectal carcinoma.